Is carboplatin-paclitaxel combination the standard treatment of elderly ovarian cancer patients?

Annals of Oncology

Volumn 18, Issue 2, 2007, Pages 213-214

  Zola, P ^a   Ferrero, A ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CARBOPLATIN; CYCLOPHOSPHAMIDE; OROSOMUCOID; PACLITAXEL; PLATINUM COMPLEX; PREALBUMIN; TAXANE DERIVATIVE;

ADVANCED CANCER; ALOPECIA; BLOOD TOXICITY; CANCER INCIDENCE; CLINICAL TRIAL; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; COMORBIDITY; CYTOREDUCTIVE SURGERY; DEPRESSION; EDITORIAL; ELDERLY CARE; HEALTH CARE; HOSPITALIZATION; HUMAN; HYPOALBUMINEMIA; LIFE EXPECTANCY; META ANALYSIS; MINI MENTAL STATE EXAMINATION; MORBIDITY; MORTALITY; MOTOR NEURON DISEASE; NEUTROPENIA; NUTRITIONAL STATUS; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SIDE EFFECT; SOMATOSENSORY DISORDER; SURVIVAL RATE; SYMPTOM; SYSTEMATIC REVIEW; THROMBOCYTE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; FEMALE; GERIATRIC ASSESSMENT; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; SURVIVAL RATE;

EID: 33847298919     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl483     Document Type: Editorial

References (19)

1. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
2. Ozols RF. Treatment goals in ovarian cancer. Int J Gynecol Cancer 2005; 15 (Suppl 1): 3-11.
3. Uyar D, Frasure HE, Markman M et al. Treatment patterns by decade of life in elderly women (≥70 years of age) with ovarian cancer. Gynecol Oncol 2005; 98: 403-408.
4. Bristow RE, Tomacruz RS, Armstrong DK et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 2002; 20: 1248-1259.
5. Wimberger P, Lehmann N, Klmmig R et al. Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol 2006; 100: 300-307.
6. Cloven NG, Manetta A, Berman ML et al. Management of ovarian cancer in patients older than 80 years of Age. Gynecol Oncol 1999; 73: 137-139.
7. Kyrgiou M, Salanti G, Pavlidis N et al. Survival benefits with diverse chemotherapy regimens for ovarian cancer: Meta-analysis of multiple treatments. J Natl Cancer Inst 2006; 98: 1655-1663.
8. Maas HA, Kruitwagen RF, Lemmens VE et al. The influence of age and comorbidity on treatment and prognosis of ovarian cancer: A population-based study. Gynecol Oncol 2005; 97: 104-109.
9. Begg CB, Carbone PP. Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group. Cancer 1983; 52: 1986-1992.
10. Ceccaroni M, D'Agostino G, Ferrandina G et al. Gynecological malignancies in elderly patients: Is age 70 a limit to standard-dose chemotherapy? An Italian retrospective toxicity multicentric study. Gynecol Oncoll 2002; 85: 445-450.
11. Higgins RV, Naumann RW, Gardner J et al. Is age a barrier to the aggressive treatment of ovarian cancer with paclitaxel and carboplatin? Gynecol Oncol 1999; 75: 464-467.
12. Villella JA, Chaudhry T, Pearl ML, et al. Comparison of tolerance of combination carboplatin and paclitaxel chemotherapy by age in women with ovarian cancer. Gynecol Oncol 2002; 86: 316-322.
13. Hershman D, Jacobson JS, McBride R et al. Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer. Gynecol Oncol 2004; 94: 540-549.
14. Trédan O, Geay J-F, Touzet S et al. Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the GINECO. Ann Oncol 2007; doi:10.1093/annonc/mdl400
15. Thigpen T, Stuart G, du Bois A et al. Clinical trials in ovarian carcinoma: Requirements for standard approaches and regimens. Ann Oncol 2005; 16 (Suppl 8): Viii13-viii19.
16. Lewis JH, Kilgore ML, Goldman DP et al. Participation of patents 65 years of age or older in cancer clinical trials. J Clin Oncol 2003; 21: 1383-1389.
17. Moore DH, Kauderer JT, Bell J et al. An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithellal ovarian cancer referred to member institutions: A Gynecologic Oncology Group study. Gynecol Oncol 2004; 94: 368-374.
18. Freyer G, Geay JF, Touzet S, et al. Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: A GINECO study. Ann Oncol 2005; 16: 1795-1800.
19. Chen H, Cantor A, Meyer J et al. Can older cancer patients tolerate chemotherapy? A prospective pilot study. Cancer 2003; 97: 1107-1114.